AbbVie Inc. (ABBV): what the price requires

At today's price, AbbVie Inc. (ABBV) is priced for +17.4% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-13 · Source: https://boothcheck.com/report/ABBV

Headline

FieldValue
TickerABBV
CompanyAbbVie Inc.
Current price$247.74/sh

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin needed13.8%
Operating margin today23.1%
Margin compression implied-9.3pp
Implied growth17.4%
Multiple paid32x operating income

The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.

Solve inputs: computed at a 7.6% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~9pp.

Reconcile: at the x-ray's 9.3% required return this reads ~6.6 years; the models below use their own rates.

How unusual the bet is: within-range

ReferenceValue
vs own history-0.02σ
cohort percentile (of 112 peers)81
sustained it ~5 years at this level44%
implied end-window share0%

Valuation X-Ray

Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset—0—
Earnings2.93x3expensive
Relative1.99x2expensive
Growth2.15x2expensive

Families that call it expensive: Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.2%); the inversion above states its own rate.

Per-Model Detail (n=7)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$294.090.84xnoFCF base $20.9B, growth 10% (input: historical growth), terminal g 4.0%, WACC 8.2%, 6yr projection
DCF Exit MultipleGrowth$280.030.88xnoExit EV/EBITDA: 28.7x / 30.7x / 32.7x (bear / base = today's held flat / bull), 6yr
Relative ValuationRelative$136.261.82xyesP/E 52.8x (blended: sector 24x + trailing (TTM) 121x), scenarios: 43.8x / 52.8x / 61.8x (bear / base = sector held flat / bull), EV/EBITDA 20.42x
Simple DDMGrowth$75.223.29xyesDPS $6.96, g=0.0% (sustainable: ROE (TTM) × retention; not the terminal-growth assumption), ke=9.3%
Two-Stage DDMGrowth$246.761.00xyesStage 1: 20% for 5yr, Stage 2: 3.5% perpetual
Simple Excess ReturnAsset——no—
Two-Stage Excess ReturnAsset——no—
Discounted Future Market CapGrowth$209.241.18xnoRev $62.8B, growth 10% (input: historical growth; tapered), Terminal P/S: 5.8x / 7.0x / 8.2x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$24.3610.17xnoEPS $2.03, growth 2% (input: historical EPS growth), PEG=60.45 (Overvalued)
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$36.786.74xnoNormalized EBIT (5y avg op income, one-time charges added back) $14.88B × (1−33%) / WACC 8.2% → EPV (no growth)
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative$114.132.17xyesEBITDA $16.10B × sector EV/EBITDA 16.0x
FCF YieldEarnings$90.682.73xyesFCF $19980.0M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$84.652.93xyesSBC-adj FCF $18.99B (FCF $19.98B − SBC $0.99B) capitalized at Kₑ
Ben Graham FormulaEarnings$65.503.78xyesEPS $2.03 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative$141.641.75xnoRevenue $62.82B × sector P/S 4.0x
PEG Fair ValueRelative$76.133.25xnoEPS $2.03 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$21.9511.29xnoEPS $2.03 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$55.6b
Net debt / NOPAT (after-tax)5.71x
Net debt / operating income (pre-tax)3.83x
Interest coverage5.0x
Share count CAGR (buyback)-0.1%
Burning cashno

Bullet Takeaways

Bull Case

The most surprising thing in AbbVie's financials is also the most reassuring once you understand it: the company shows negative book equity, the kind of figure that makes mechanical screens flag distress, on a business that produces around $20 billion of free cash flow a year. The negative equity is not a sign of trouble. It is what happens when a company makes a very large acquisition, in AbbVie's case Allergan, and then returns enormous cash to shareholders through dividends and buybacks, drawing book equity down even as economic value compounds. A buyer who reads only the balance-sheet headline misses the point. The cash engine underneath is one of the strongest in pharmaceuticals.

That cash engine has just cleared the hurdle that defined the bear case for years. Humira lost U.S. patent protection in 2023 and faced a wave of biosimilars, and the question was always whether AbbVie could replace its signature blockbuster. The first-quarter 2026 result answered it. Skyrizi generated $4.48 billion, up about 31% year over year, and Rinvoq $2.12 billion, up about 23%, while Humira fell 38.6% to $688 million. The FY2025 10-K shows the same trajectory at full-year scale, with Skyrizi net revenue up 50% and Rinvoq up 39% in 2025 on strong share uptake across indications (FY2025 10-K, accession 0001551152-26-000008). The two successor drugs now generate multiples of what the declining Humira contributes. The transition the market feared is not a future risk, it is a completed fact.

The confidence shows in the guidance and the income. AbbVie beat first-quarter expectations with adjusted EPS of $2.65, raised full-year adjusted EPS guidance to $14.08 to $14.28, and lifted its 2026 sales expectations for both Skyrizi and Rinvoq, now targeting roughly $21.6 billion and $10.2 billion respectively. Total revenue grew 12.4% to about $15 billion. On top of that AbbVie pays a substantial, long-growing dividend and carries one of the deepest pipelines in immunology, oncology, and neuroscience, with the cash flow to keep acquiring assets. The bull case is a company that just proved it could outgrow the largest patent cliff in its history, now compounding double digits with a strengthening pipeline and a dividend backed by real cash. The scary balance-sheet optics are the tell of an aggressive, successful capital-return strategy, not a warning.

Bear Case

The bear case is the oldest one in pharma: today's growth drivers are tomorrow's patent cliffs, and AbbVie is paying top-of-sector prices for a position at what may be peak immunology earnings. Skyrizi and Rinvoq are spectacular now, but they are on the same clock Humira was. Their exclusivity windows are finite, biosimilar and competitive pressure will arrive, and when it does the company will need the next pair of multi-billion-dollar drugs to repeat the trick. The market is currently extrapolating the immunology duo's growth as if it runs indefinitely, when the entire AbbVie playbook is a reminder that even a $20-billion-a-year drug eventually rolls over. Buying a pharma at the top of the cycle for its current blockbusters is how investors have repeatedly overpaid in this sector.

The leverage is the second concern, and here the negative book equity does carry a real edge. Net debt is about $55.6 billion, roughly 3.6 times operating income, and interest coverage is around 5.3 times. That is a manageable but meaningful debt load, built up to fund the Allergan acquisition and the capital returns. It means AbbVie has less balance-sheet flexibility than the cash flow alone suggests, and that the large business-development deals the growth strategy depends on must be funded from cash flow or more debt rather than from a fortress balance sheet. If a pipeline setback or a faster-than-expected erosion of a key drug hits while leverage is elevated, the company has less room to absorb it.

The price compounds both risks. At about 29 times operating income, the multiple sits at the very top of the pharma peer distribution, well beyond the upper quartile. No valuation family reaches $217 on a conservative read: the relative valuation lands near $127, the EV/EBITDA comparison near $114, and the FCF-yield methods in the $80s to low $90s. The two-stage dividend model, which assumes a sharp growth phase, is the only method that approaches the price near $247. So a buyer is paying a premium-to-peers multiple for a company whose growth, however real today, runs on patent-protected drugs with finite lives and whose balance sheet carries real leverage. The bear case is not that AbbVie is weak. It is that it is priced as though its current immunology peak is a permanent plateau, when its own history says peaks in this business are temporary.

Valuation

Inverting the price gives the cleanest read. At $217 the market pays about 29 times company-wide operating income, which works backward to roughly 14% annual operating growth sustained for five years, solved at a 7.5% cost of capital. Treat the figure as approximate. Three comparisons frame it: the implied near-term pace is within what AbbVie has recently delivered, the multiple sits at the very top of the peer distribution well beyond the upper quartile, and on the historical base rate about half of comparable fast-growers sustained a pace like that for five years. The read comes out within range on the company's own trajectory but expensive relative to peers, with the stretch being how long the growth persists rather than the rate.

The valuation X-ray is unusually constrained here, and the reason is instructive. AbbVie's negative book equity trips a set of mechanical distress flags, neg book equity, neg retained earnings, a weak Altman read, which knock out the cash-flow projection methods and all the book-value methods. Those flags are accounting artifacts of the Allergan deal and the capital returns, not genuine distress, but they leave the X-ray running on only the relative and earnings-power families. Those land below the price: relative valuation near $127, EV/EBITDA near $114, and the capitalized-FCF methods in the $80s to low $90s. The two-stage dividend model reaches near $247 because it assumes a strong growth stage. So on the methods that can run, the price is above the conservative frames and only the growth-assuming method reaches it.

The leverage is real and computable here: net debt near $55.6 billion is about 3.6 times operating income with coverage around 5.3 times, a manageable load on this cash flow but not a fortress. The valuation conclusion is that the price is defensible on AbbVie's demonstrated double-digit growth and strong cash generation, but it is a top-of-sector multiple that assumes the immunology franchise compounds for years before facing its own erosion. The buyer is paying for continued execution at a premium, with the dividend and cash flow providing real support underneath.

Catalysts

The first-quarter 2026 report, released at the end of April, was a clear beat-and-raise. Revenue grew 12.4% to about $15 billion and adjusted EPS came in at $2.65 against a roughly $2.59 to $2.60 consensus. The immunology engine drove it: Skyrizi reached $4.48 billion, up 30.9% year over year, and Rinvoq $2.12 billion, up 23.3%, while Humira continued its expected decline, down 38.6% to $688 million. On the strength of the quarter AbbVie raised full-year adjusted EPS guidance to $14.08 to $14.28 from a prior $13.96 to $14.16, and lifted its 2026 sales targets for Skyrizi to roughly $21.6 billion and Rinvoq to roughly $10.2 billion.

The forward catalysts center on the immunology run-rate and the pipeline. The items to watch are whether Skyrizi and Rinvoq sustain their growth toward the raised full-year targets, the pace of Humira's biosimilar erosion, and pipeline readouts and business-development moves across immunology, oncology, neuroscience, and aesthetics that would define the next generation of growth drivers beyond the current duo. Drug-pricing policy and any tariff or trade actions affecting pharmaceuticals are external swing factors. The next quarterly print, due in late July, will show whether the immunology momentum and the raised guidance are tracking. Continued double-digit growth in Skyrizi and Rinvoq with pipeline progress would extend the post-Humira story; any slowdown in the duo or a pipeline setback would test a top-of-sector valuation.

Sources: AbbVie Q1 2026 financial results (prnewswire.com, 2026-04-29); Qz earnings beat and raise coverage (qz.com); AlphaStreet post-Humira analysis (news.alphastreet.com).

Peer Cohorts (Per Segment, With Filing Citations)

Pharmaceutical Products (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive ABBV report on boothcheck